Despite the U.S. Food and Drug Administration’s approval of a digital-ingestion-tracking-system drug in 2017, researchers at the University of Illinois at Chicago caution that it is premature for providers to use such "smart" pills in clinical settings, Health Data Management reports. The researchers state there is no evidence that such technology is beneficial to patients, and, instead, they argue it poses a danger to the patient-provider relationship. In a paper published in "The American Journal of Bioethics," researchers argue the use of digital medicine raises concerns related to patient privacy, consent and data sharing, adding, "Digital pharmacopic surveillance moves beyond the nudge in that it appears to eliminate choice and give more control to providers and private companies, which come to control and in many cases claim ownership of patient data." 
Full Story